Mylan Deals a Blow to Teva Pharmaceutical
Generic drugmakers Mylan (NASDAQ: MYL) and Teva Pharmaceutical (NYSE: TEVA) usually deal blows to brand-name drug manufacturers, not each other, but that changed last week when the Food and Drug Administration approved Mylan's generic version of Teva Pharmaceutical's Copaxone, a best-selling drug with $4 billion in annual sales. Here's what this news means to investors in these companies.
Teva Pharmaceutical is best known for making generic drugs, but it generates about 20% of its top-line sales from Copaxone. The latter's sales of $1.02 billion in the second quarter accounted for only a little less than half of Teva Pharmaceutical's specialty drug segment sales.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€15.95
0.320%
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 19 € there is a slightly positive potential of 19.12% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.95 €.
